| Content Analysis and Basic Evaluation of the Third Revised Version of China's Provisions for Drug Registration |
1 |
| Global Human Embryonic Stem Cell Laws and Policies and Their Influence on Stem Cell Tourism |
1 |
| Patentability Standards for Follow-On Pharmaceutical Innovation |
1 |
| Disclosure of Vaccine Risk and Emergency Legislation in China |
1 |
| The Regulation of Genetically Modified Food in China |
1 |
| Construction and Perfection of the Responsibility of Third-Party Platform Providers of the Online Food Trade in China |
1 |
| Nalpropion Pharm., Inc. v. Actavis Labs. FL, Inc. United States Court of Appeals of the Federal Circuit, 2019 No. 2018- 2019 WL 3819335 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Eli Lilly & Co. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2019 933 F.3d 1320 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Study on the Patent Infringement Litigation and Patent Invalidation Trial Processes in the Biopharmaceutical Industry in China |
0 |
| Compulsory Licenses on Patents in Germany |
0 |
| Athena Diagnostics, Inc. v. Mayo Collaborative Servs. United States Court of Appeals of the Federal Circuit, 2019 927 F.3d 1333 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Orexo AB v. Actavis Elizabeth LLC United States Court of Appeals of the Federal Circuit, 2018 903 F.3d 1265 |
0 |
| Roche Molecular Sys., Inc. v. Cepheid United States Court of Appeals of the Federal Circuit, 2018 905 F.3d 1363 |
0 |
| EI DuPont de Nemours & Co. v. Synvina CV United States Court of Appeals of the Federal Circuit, 2018 904 F.3d 996 |
0 |
| Regents of Univ. of California v. Broad Inst., Inc. United States Court of Appeals of the Federal Circuit, 2018 903 F.3d 1286 |
0 |
| Status and Prospects for Regulation of Genetically Modified Crops in China |
0 |
| The Freedom to Not Disclose: A First Amendment Analysis of the National Bioengineered Food Disclosure Standard |
0 |
| In re Qapsule Techs., Inc. United States Court of Appeals of the Federal Circuit, 2019 No. 2018- 2019 WL 1110899 |
0 |
| Nat. Alternatives Int'l, Inc. v. Creative Compounds, LLC United States Court of Appeals of the Federal Circuit, 2019 918 F.3d 1338 |
0 |
| Cleveland Clinic Found. v. True Health Diagnostics LLC United States Court of Appeals of the Federal Circuit, 2019 No. 2018- 2019 WL 1452697 |
0 |
| Grunenthal GMBH v. Alkem Labs. Ltd. United States Court of Appeals of the Federal Circuit, 2019 919 F.3d 1333 |
0 |
| Endo Pharm. Inc. v. Teva Pharm. USA, Inc. United States Court of Appeals of the Federal Circuit, 2019 919 F.3d 1347 |
0 |
| Forest Labs., LLC v. Sigmapharm Labs., LLC United States Court of Appeals of the Federal Circuit, 2019 918 F.3d 928 |
0 |
| Plasma Concentration-Time Profile as an Indefinite Claim Term: A Lesson from Forest Labs., Inc. v. Teva Pharm. USA, Inc. |
0 |
| Congress Considering Legislation Aimed at Increasing Competition in Pharmaceuticals |
0 |
| Mylan Pharm. Inc. v. Research Corp. Techs., Inc. |
0 |
| Momenta Pharm., Inc. v. Bristol-Myers Squibb Co. |
0 |
| Patenting of Genetic Research in Europe and the US: A Questionable Future for Diagnostic Methods and Personalized Medicines |
0 |
| Helsinn Healthcare v. Teva Pharm. USA |
0 |
| Brigham & Women's Hosp., Inc. v. Perrigo Co. United States Court of Appeals of the Federal Circuit, 2019 2019 WL 990816 (Nonprecedential decision) Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Amerigen Pharm. Ltd. v. UCB Pharma GmbH |
0 |
| The Legalization of the Security Protection, Circulation and Application of Biological Big Data in China: Current Status and Outlook |
0 |
| Illumina, Inc. v. Ariosa Diagnostics, Inc. Northern District of California, 2018 2018 WL 6735143 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Yeda Research v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2018 906 F.3d 1031 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| In Re: Copaxone Consol. Cases United States Court of Appeals of the Federal Circuit, 2018 906 F.3d 1013 Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN* |
0 |
| Gensetix, Inc. v. Baylor Coll. of Med. Southern District of Texas, 2018 2018 WL 6488063 |
0 |
| Regulating Human Genome Editing in Australia: Overdue Legislative Review |
0 |
| Disharmonization in the Regulation of Transgenic Plants in Europe |
0 |
| Gaming the Regulatory System for Genetically Modified Crops in China |
0 |
| Not Just a Base, Use of Swelling Agent in a Claim for Emulsion Polymerization Patents: A Lesson from Organik Kimya AS v. Rohm & Haas Co. |
0 |
| How Can China Solve the Problem of Bad Vaccines after Changchun Changsheng? |
0 |
| Taxing Issues for Intellectual PropertyA UK Debate |
0 |
| Ensuring Expeditious Entry: Korea and the US Regulatory Pathway for Bringing Biosimilars to Market |
0 |
| Sometimes Less Is MoreDisclaimer Practice in the European Patent Office |
0 |
| Ethical Review in Granting Invention Patents to Human Embryonic Stem Cells in Chinawith the Patent Dispute over the Nuclear Reprogramming Factor as a Case |
0 |
| Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China |
0 |
| Trade Secret Protection of Genetically Engineered Rice Through the Economic Espionage Act: A Lesson from United States v. Weiqiang Zhang |
0 |
| Studies of Legal Issues Related to the Implementation of the Patent Linkage System in China |
0 |
